Could the time you take chemo make a difference? new trial investigates

NCT ID NCT06850766

Recruiting now Symptom relief Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This pilot study looks at whether taking the chemotherapy drug temozolomide at a specific time of day (morning or evening) is practical for people with glioblastoma, a type of brain cancer. Fifty adults who have completed surgery and radiation will be randomly assigned to take their medication either within 2 hours of waking or within 2 hours of bedtime. The main goal is to see if patients can stick to the assigned schedule, which could help plan a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temozolomide (TMZ)
What this could lead to: If successful, this study could show that timing chemotherapy to the body's natural rhythms is practical, paving the way for a larger trial to see if it improves outcomes.
What could go wrong: This is a small pilot study with only 50 participants, so results may not apply broadly. It tests feasibility, not effectiveness, so even if timing works, it may not improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM) IDH-WILDTYPE GLIOBLASTOMA

Contacts and locations

Locations

London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada
The Ottawa Hospital Cancer Centre
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.